Medidata Solutions (NASDAQ:MDSO) issued its quarterly earnings data on Thursday. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10, Bloomberg Earnings reports. The business had revenue of $141.20 million during the quarter, compared to analyst estimates of $140.65 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The firm’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter last year, the business earned $0.33 EPS.
Shares of Medidata Solutions (NASDAQ MDSO) traded down $4.76 during mid-day trading on Thursday, hitting $61.62. 1,550,852 shares of the stock traded hands, compared to its average volume of 504,052. The firm has a market cap of $3,825.69, a P/E ratio of 94.83, a price-to-earnings-growth ratio of 3.39 and a beta of 1.58. Medidata Solutions has a one year low of $50.00 and a one year high of $85.92. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61.
A number of brokerages recently issued reports on MDSO. BidaskClub upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Dougherty & Co assumed coverage on shares of Medidata Solutions in a research report on Thursday, November 2nd. They set a “neutral” rating for the company. Royal Bank of Canada reissued a “hold” rating and set a $80.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Deutsche Bank assumed coverage on shares of Medidata Solutions in a research report on Friday, December 8th. They set a “buy” rating and a $78.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.54.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fortaleza Asset Management Inc. acquired a new stake in Medidata Solutions in the 3rd quarter valued at $155,000. Polen Capital Management LLC acquired a new stake in Medidata Solutions in the 3rd quarter valued at $205,000. Cubist Systematic Strategies LLC acquired a new stake in Medidata Solutions in the 2nd quarter valued at $227,000. Hanseatic Management Services Inc. grew its position in Medidata Solutions by 14,915.0% in the 3rd quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock valued at $234,000 after purchasing an additional 2,983 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in Medidata Solutions in the 3rd quarter valued at $248,000. 97.52% of the stock is owned by institutional investors and hedge funds.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.